<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">31183987</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1758-2652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the International AIDS Society</Title>
          <ISOAbbreviation>J Int AIDS Soc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.</ArticleTitle>
        <Pagination>
          <StartPage>e25322</StartPage>
          <MedlinePgn>e25322</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e25322</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jia2.25322</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION">In developed countries, breastfeeding is not recommended for women living with human immunodeficiency virus (WLWH). However, lactation symptoms can be distressing for women who choose not to breastfeed. There is currently no universal guideline on the most appropriate options for prevention or reduction of lactation symptoms amongst WLWH. This review describes the evidence base for using cabergoline, a dopaminergic agonist, for the post-partum inhibition of lactation for WLWH.</AbstractText>
          <AbstractText Label="METHODS">A scoping review of post-partum pharmaceutical lactation inhibition specific for WLWH was conducted using searches in PubMed, Medline Ovid, EBM Reviews Ovid, Embase, Web of Science and Scopus until 2019. A narrative review of cabergoline pharmacologic properties, therapeutic efficacy, tolerability data and drug interaction data relevant to lactation inhibition was then conducted.</AbstractText>
          <AbstractText Label="RESULTS AND DISCUSSION">Among 1366 articles, the scoping review identified 13 relevant publications. Eight guidelines providing guidance regarding lactation inhibition for WLWH and two surveys of medical practice on this topic in UK have been published. Three studies have evaluated the use of pharmaceutical agents in WLWH. Two of these studies evaluated cabergoline and reported it to be an effective method of lactation inhibition in this population. The third study evaluated ethinyl estradiol and bromocriptine use and showed poor efficacy. Cabergoline is a long-acting dopamine D2 agonist and ergot derivative that inhibits prolactin secretion and suppresses physiologic lactation when given as a single oral dose of 1 mg after delivery. Cabergoline is at least as effective as bromocriptine for lactation inhibition with success rates between 78% and 100%. Transient, mild to moderate adverse events to cabergoline are described in clinical trials. Few drug interactions exist as cabergoline is neither a substrate nor an inducer/inhibitor of hepatic cytochrome P450 isoenzymes. There are no reported clinically significant drug-drug interactions between cabergoline and any antiretroviral medications including protease inhibitors.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Cabergoline is a safe and effective pharmacologic option for the prevention of physiological lactation and associated physical symptoms in non-breastfeeding women. Future studies should focus on its safety, efficacy and acceptability among WLWH.</AbstractText>
          <CopyrightInformation>© 2019 The Authors. Journal of the International AIDS Society published by John Wiley &amp; Sons Ltd on behalf of the International AIDS Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tulloch</LastName>
            <ForeName>Karen J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, BC Women's Hospital and Health Centre, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Women's Health Research Institute, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dodin</LastName>
            <ForeName>Philippe</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>CHU Sainte-Justine, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tremblay-Racine</LastName>
            <ForeName>Fannie</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>CHU Sainte-Justine, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elwood</LastName>
            <ForeName>Chelsea</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Women's Health Research Institute, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Money</LastName>
            <ForeName>Deborah</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Women's Health Research Institute, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boucoiran</LastName>
            <ForeName>Isabelle</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0001-9545-6024</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Int AIDS Soc</MedlineTA>
        <NlmUniqueID>101478566</NlmUniqueID>
        <ISSNLinking>1758-2652</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001942" MajorTopicYN="N">Breast Feeding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007774" MajorTopicYN="N">Lactation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">
HIV
</Keyword>
        <Keyword MajorTopicYN="Y">cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">lactation inhibition</Keyword>
        <Keyword MajorTopicYN="Y">lactation suppression</Keyword>
        <Keyword MajorTopicYN="Y">post-partum</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31183987</ArticleId>
        <ArticleId IdType="pmc">PMC6558502</ArticleId>
        <ArticleId IdType="doi">10.1002/jia2.25322</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
John‐Stewart G, Mbori‐Ngacha D, Ekpini R, Janoff EN, Nkengasong J, Read JS, et al. Breast‐feeding and Transmission of HIV‐1. J Acquir Immune Defic Syndr. 2004;35(2):196–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3382106</ArticleId>
            <ArticleId IdType="pubmed">14722454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet. 1992;340(8819):585–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1355163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Loutfy M, Aden M, Wu W, Serghides L. Systematic review of perinatal HIV transmission through breastfeeding for up to twelve months when the mother has viral suppression with combination antiretroviral therapy. 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, BC, Canada; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bispo S, Chikhungu L, Rollins N, Siegfried N, Newell M‐L. Postnatal HIV transmission in breastfed infants of HIV‐infected women on ART: a systematic review and meta‐analysis. J Int AIDS Soc. 2017;20(1):21251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5467610</ArticleId>
            <ArticleId IdType="pubmed">28362072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission
. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. 2018.  [cited 2018 Dec 7]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
Bitnun A, Brophy J, Samson L, Alimenti A, Kakkar F, Lamarre V, et al. Prevention of vertical HIV transmission and management of the HIV‐exposed infant in Canada in 2014. Can J Infect Dis Med Microbiol. 2014;25(2):75–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4028671</ArticleId>
            <ArticleId IdType="pubmed">24855474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast‐feeding in Botswana. N Engl J Med. 2010;362(24):2282–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2999916</ArticleId>
            <ArticleId IdType="pubmed">20554983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Committee on Pediatric Aids
. Infant feeding and transmission of human immunodeficiency virus in the United States. Pediatrics. 2013;131(2):391–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23359577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Money D, Tulloch K, Boucoiran I, Caddy S; Infectious Diseases C
, Yudin MH, et al. Guidelines for the care of pregnant women living with HIV and interventions to reduce perinatal transmission: executive summary. J Obstet Gynaecol Can. 2014;36(8):721–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25222168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
British HIV Association Guidelines for the management of HIV infection in pregnant women HIV Medicine. 2018.  [cited 2018 Dec 7]. Available from: http://www.bhiva.org/pregnancy-guidelines.aspx
</Citation>
        </Reference>
        <Reference>
          <Citation>
European AIDS Clinical Society
. European Guidelines for treatment of HIV‐positive adults. 2018.  [cited 2018 Dec 7]. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
</Citation>
        </Reference>
        <Reference>
          <Citation>
Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev. 2012;12(9):CD005937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6599849</ArticleId>
            <ArticleId IdType="pubmed">22972088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spitz AM, Lee NC, Peterson HB. Treatment for lactation suppression: little progress in one hundred years. Am J Obstet Gynecol. 1998;179
6 Pt 1:1485–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9855585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Department of Health and Human Services. Food and Drug Administration. Sandoz Pharmaceuticals Corp
. Bromocriptine mesylate (Parlodel) for the prevention of physiological lactation; opportunity for a hearing on a proposal to withdraw approval of the indication. 1994.  [cited 2019 Mar 15]. Available from: https://www.gpo.gov/fdsys/pkg/FR-1994-08-23/html/94-20562.htm
</Citation>
        </Reference>
        <Reference>
          <Citation>
European Medicines Agency
. CMDh endorses restricted use of bromocriptine for stopping breast milk production. 2014.  [cited 2019 Mar 15]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/08/news_detail_002157.jsp&amp;mid=WC0b01ac058004d5c1
</Citation>
        </Reference>
        <Reference>
          <Citation>
Grueger B; Canadian Paediatric Society, Community Paediatrics Committee
. Weaning from the breast. Paediatr Child Health. 2013;18(4):210–1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3805627</ArticleId>
            <ArticleId IdType="pubmed">24421692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrari C, Piscitelli G, Crosignani PG. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod. 1995;10(7):1647–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8582955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22(10):1568–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26243714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dostinex Product Monograph. Kirkland. Quebec: Pfizer Canada Inc. 2013.  [cited 2019 Apr 15]. Available from: https://www.pfizer.ca/sites/g/files/g10050796/f/201710/Dostinex_PM_E.pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
British National Formulary
. Cabergoline. 2018.  [cited 2019 Mar 15]. Available from: https://bnf.nice.org.uk/drug/cabergoline.html
</Citation>
        </Reference>
        <Reference>
          <Citation>
Chantry CJ, Wiedeman J, Buehring G, Peerson JM, Hayfron K, K'Aluoch O, et al. Effect of flash‐heat treatment on antimicrobial activity of breastmilk. Breastfeed Med. 2011;6(3):111–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3143386</ArticleId>
            <ArticleId IdType="pubmed">21091243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haute Autorité de Santé; Commission de la transparence
. Avis 7 mai. 2014.  CABERGOLINE SANDOZ 0,5 mg, comprimé sécable [cited 2019 Mar 15]. Available from: https://www.has-sante.fr/portail/upload/docs/evamed/CT-13522_CABERGOLINE_SANDOZ_PIS_INS_Avis2_CT13522.pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
Dostinex‐cabergoline tablet Product. Monograph, NY: Pharmacia &amp; Upjohn Company. 2014.  [cited 2019 Mar 15]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=1776
</Citation>
        </Reference>
        <Reference>
          <Citation>
Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26134548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19631507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Ruiter A, Brocklehurst P. HIV infection and pregnancy. Int J STD AIDS. 1998;9(11):647–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9863576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furner V. HIV and pregnancy. 2016.  [cited 2019 Mar 15]. Available from: http://hivmanagement.ashm.org.au/index.php/populations-and-situations/hiv-in-pregnancy-children-and-transitioning-adolescents/hiv-and-pregnancy
</Citation>
        </Reference>
        <Reference>
          <Citation>
World Health Organization
. Updates on HIV and infant feeding guideline. 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>
World Health Organization
. Guidelines on HIV and infant feeding. 2010.</Citation>
        </Reference>
        <Reference>
          <Citation>
Naver L, Albert J, Carlander C, Flamholc L, Gisslen M, Josephson F, et al. Prophylaxis and treatment of HIV‐1 infection in pregnancy ‐ Swedish Recommendations 2013. Scan J Infect Dis. 2014;46(6):401‐411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24754479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Navér L, Albert J, Carlander C, Flamholc L, Gisslén M, Karlström O, et al. Prophylaxis and treatment of HIV‐1 infection in pregnancy – Swedish Recommendations. Infect Dis. 2017;50(7):495–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29363407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, et al. British HIV association and children's HIV association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008;9(7):452–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18840151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sénat M‐V, Sentilhes L, Battut A, Benhamou D, Bydlowski S, Chantry A, et al. Postpartum practice: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2016;202:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27155443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Groupe d'experts pour la prise en charge du VIH
. Prise en charge médicale des personnes vivant avec le VIH. Désir d'enfant et grossesse. 2017.  [cited 2019 Mar 15]. Available from: https://cns.sante.fr/wp-content/uploads/2017/11/experts-vih_grossesse.pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev. 2012;12(9):CD005937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6599849</ArticleId>
            <ArticleId IdType="pubmed">22972088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Buhendwa L, Zachariah R, Teck R, Massaquoi M, Kazima J, Firmenich P, et al. Cabergoline for suppression of puerperal lactation in a prevention of mother‐to‐child HIV‐transmission programme in rural Malawi. Trop Doct. 2008;38(1):30–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18302861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Piya‐Anant M, Worapitaksanond S, Sittichai K, Saechua P, Nomrak A. The combined oral contraceptive pill versus bromocriptine to suppress lactation in puerperium: a randomized double blind study. J Med Assoc Thai. 2004;87(6):670–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15279347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Humphrey S, Baechler M, Schiff M, Hitti J. Cabergoline for lactation suppression among HIV+ and HIV‐ women. Top Antivir Med. 2018;26
Suppl 1:362s.</Citation>
        </Reference>
        <Reference>
          <Citation>
Pammi M, Carlin EM. Survey of lactation suppression in HIV‐positive pregnant women. Int J STD AIDS. 2012;23(4):280–1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22581953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gilleece Y. National survey of management of Pregnancy in women living with HIV. London, UK: British HIV Association Conference; 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>
Ratcliffe J, Ades AE, Gibb D, Sculpher MJ, Briggs AH. Prevention of mother‐to‐child transmission of HIV‐1 infection: alternative strategies and their cost‐effectiveness. AIDS. 1998;12(11):1381–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9708419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11015620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12844325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Melis GB, Gambacciani M, Paoletti AM, Beneventi F, Mais V, Baroldi P, et al. Dose‐related prolactin inhibitory effect of the new long‐acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women. J Clin Endocrinol Metab. 1987;65(3):541–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3624413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Melis GB, Mais V, Paoletti AM, Beneventi F, Gambacciani M, Fioretti P. Prevention of puerperal lactation by a single oral administration of the new prolactin‐inhibiting drug, cabergoline. Obstet Gynecol. 1988;71
3 Pt 1:311–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3279351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caballero‐Gordo A, Lopez‐Nazareno N, Calderay M, Caballero JL, Mancheño E, Sghedoni D. Oral cabergoline. Single‐dose inhibition of puerperal lactation. J Reprod Med. 1991;36(10):717–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1683403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giorda G, de Vincentiis S, Motta T, Casazza S, Fadin M, D'Alberton A. Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery. Gynecol Obstet Invest. 1991;31(2):93–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2037265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nisha S, Uma S, Vineeta S. Role of newer drug cabergoline in lactation suppression as compared to estrogen‐androgen combination. J Obst Gynecol India. 2009;59(2):152–5.</Citation>
        </Reference>
        <Reference>
          <Citation>
European Multicentre Study Group for Cabergoline in Lactation Inhibition
. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. BMJ. 1991;302(6789):1367–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1670075</ArticleId>
            <ArticleId IdType="pubmed">1676318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
AlSaad D, ElSalem S, Abdulrouf PV, Thomas B, Alsaad T, Ahmed A, et al. A retrospective drug use evaluation of cabergoline for lactation inhibition at a tertiary care teaching hospital in Qatar. Ther Clin Risk Manag. 2016;12:155–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754102</ArticleId>
            <ArticleId IdType="pubmed">26929627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Snellen M, Power J, Blankley G, Galbally M. Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: a systematic review. Aust N Z J Obstet Gynaecol. 2016;56(4):336–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27297803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Athanasoulia AP, Sievers C, Ising M, Brockhaus AC, Yassouridis A, Stalla GK, et al. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012;167(3):327–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22672924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Christensen J, Dupont E, ØStergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Mov Disord. 2002;17(6):1360–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12465083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakatsuka A, Nagai M, Yabe H, Nishikawa N, Nomura T, Moritoyo H, et al. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. J Pharmacol Sci. 2006;100(1):59–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16410677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cabergoline [Internet]. Lexicomp, Inc. 2017.  [cited 2019 Mar 15]. Available from: http://online.lexi.com. Subscription required to view</Citation>
        </Reference>
        <Reference>
          <Citation>
Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug‐drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20004485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Avihingsanon A, Ramautarsing RA, Suwanpimolkul G, Chetchotisakd P, Bowonwatanuwong C, Jirajariyavej S, et al. Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warning. Top Antivir Med. 2014;21(5):165–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6148849</ArticleId>
            <ArticleId IdType="pubmed">24531557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg. 2003;37(3):676–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12618710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caballero‐Granado FJ, Viciana P, Cordero E, Gómez‐Vera MJ, del Nozal M, López‐Cortés LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother. 1997;41(5):1207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC163885</ArticleId>
            <ArticleId IdType="pubmed">9145904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fröhlich G, Kaplan V, Amann‐Vesti B. Holy fire in an HIV‐positive man: a case of 21st‐century ergotism. CMAJ. 2010;182(4):378–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831703</ArticleId>
            <ArticleId IdType="pubmed">20048008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine, and ritonavir. Clin Infect Dis. 2003;37(5):e72–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12942422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW. Fatal ergotism induced by an HIV protease inhibitor. Headache. 2002;42(7):694–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12482227</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
